Clinical Trials
13 trialsNCT03881488 2026-04-17
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Phase 1 Completed
NCT04332653 2026-03-09
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
Phase 1/2 Completed
NCT04924101 2025-07-23
KEYNOTE-B99
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04358237 2025-06-04
LUPER
Blanco, Dr Antonio Calles MD
Phase 1/2 Completed
NCT02922764 2025-03-26
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Inspirna, Inc.
Phase 1 Completed
NCT03761914 2024-11-19
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Sellas Life Sciences Group
Phase 1/2 Completed
NCT02580994 2023-12-11
REACTION
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT03841110 2023-05-01
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Completed
NCT03849469 2023-03-30
DUET-4
Xencor, Inc.
Phase 1 Completed
NCT03066778 2022-10-03
KEYNOTE-604
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03371979 2021-11-04
Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer
Aeglea Biotherapeutics
Phase 1/2 Completed
NCT01840579 2021-06-22
MK-3475-011
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT02551432 2020-02-10
MISP-MK3475
Seoul National University Hospital
Phase 2 Completed